182 related articles for article (PubMed ID: 20238251)
1. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation.
Schmitt TM; Phillips M; Sawyer RG; Northup P; Hagspiel KD; Pruett TL; Bonatti HJ
Dig Dis Sci; 2010 Nov; 55(11):3224-34. PubMed ID: 20238251
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation.
Lee JG; Lee J; Lee JJ; Song SH; Ju MK; Choi GH; Kim MS; Choi JS; Kim SI; Joo DJ
Medicine (Baltimore); 2016 Jun; 95(23):e3711. PubMed ID: 27281070
[TBL] [Abstract][Full Text] [Related]
3. Thymoglobulin for steroid-resistant immune-mediated graft dysfunction during simeprevir-based antiviral treatment for post-transplantation hepatitis C: case report.
Takeishi K; Ikegami T; Yoshizumi T; Itoh S; Harimoto N; Harada N; Tsujita E; Kimura Y; Yamashita Y; Saeki K; Oki E; Shirabe K; Maehara Y
Transplant Proc; 2015 Apr; 47(3):794-5. PubMed ID: 25891734
[TBL] [Abstract][Full Text] [Related]
4. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.
Horton PJ; Tchervenkov J; Barkun JS; Rochon C; Chaudhury PK; Znajda TL; Martinie JB; Metrakos P
J Gastrointest Surg; 2005; 9(7):896-902. PubMed ID: 16137581
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.
McTaggart RA; Terrault NA; Vardanian AJ; Bostrom A; Feng S
Liver Transpl; 2004 Aug; 10(8):975-85. PubMed ID: 15390322
[TBL] [Abstract][Full Text] [Related]
6. Antibody Drug Treatment for Steroid-Resistant Rejection After Pediatric Living Donor Liver Transplantation: A Single-Center Experience.
Hirata Y; Sanada Y; Urahashi T; Ihara Y; Yamada N; Okada N; Katano T; Otomo S; Ushijima K; Mizuta K
Transplant Proc; 2018; 50(1):60-65. PubMed ID: 29407332
[TBL] [Abstract][Full Text] [Related]
7. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
8. A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients.
Benjamin MM; Dasher KJ; Trotter JF
Transplantation; 2014 Feb; 97(4):470-3. PubMed ID: 24142032
[TBL] [Abstract][Full Text] [Related]
9. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
Kerkar N; Morotti RA; Iyer K; Arnon R; Miloh T; Sturdevant M; Suchy F; Florman S; Emre S
Clin Transplant; 2011; 25(6):E584-91. PubMed ID: 21919961
[TBL] [Abstract][Full Text] [Related]
10. Steroid-resistant acute rejections after liver transplant.
Aydogan C; Sevmis S; Aktas S; Karakayali H; Demirhan B; Haberal M
Exp Clin Transplant; 2010 Jun; 8(2):172-7. PubMed ID: 20565375
[TBL] [Abstract][Full Text] [Related]
11. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.
Jain A; Demetris AJ; Kashyap R; Blakomer K; Ruppert K; Khan A; Rohal S; Starzl TE; Fung JJ
Liver Transpl; 2001 Jul; 7(7):623-30. PubMed ID: 11460230
[TBL] [Abstract][Full Text] [Related]
12. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients.
Urbani L; Mazzoni A; Catalano G; De Simone P; Vanacore R; Pardi C; Bortoli M; Biancofiore G; Campani D; Perrone V; Mosca F; Scatena F; Filipponi F
Transplant Proc; 2004 Dec; 36(10):3068-70. PubMed ID: 15686696
[TBL] [Abstract][Full Text] [Related]
13. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
14. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis.
Togashi J; Sugawara Y; Tamura S; Kaneko J; Yamashiki N; Aoki T; Hasegawa K; Kokudo N
Biosci Trends; 2011; 5(2):57-60. PubMed ID: 21572248
[TBL] [Abstract][Full Text] [Related]
16. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
[TBL] [Abstract][Full Text] [Related]
17. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
[TBL] [Abstract][Full Text] [Related]
18. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report.
Nakano R; Ohira M; Ishiyama K; Ide K; Kobayashi T; Tahara H; Shimizu S; Arihiro K; Imamura M; Chayama K; Tanaka Y; Ohdan H
Transplant Proc; 2017 Sep; 49(7):1634-1638. PubMed ID: 28838454
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
Ravichandran P; Natrajan T; Jaganathan R
Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
